Advertisement

Topics

Pfizer gains Breakthrough designation for PF-04965842 in atopic dermatitis

07:13 EST 15 Feb 2018 | thePharmaLetter

The once-daily oral Janus kinase 1 (JAK1) inhibitor PF-04965842 has received Breakthrough Therapy designation…

Original Article: Pfizer gains Breakthrough designation for PF-04965842 in atopic dermatitis

NEXT ARTICLE

More From BioPortfolio on "Pfizer gains Breakthrough designation for PF-04965842 in atopic dermatitis"

Advertisement
Quick Search
Advertisement
Advertisement